BridgeMD
New treatment option for Obstructive Sleep Apnea
Official title The Adherence of Proactive Sleep Apnea Therapy
ClinicalTrials.gov ID: NCT06319482
What this study is testing
- What it's testing
- The goal of this clinical trial is to compare the adherence to Positive Airway Pressure (PAP) therapy for newly diagnosed Obstructive Sleep Apnea (OSA) patients. The main question(s) it aims to answer are: 1.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Must have a new diagnosis of moderate or severe OSA (i.e., AHI \> 15 events/hour).
- Must be 18-70 years old.
- No history of self-reported, uncontrolled, severe cardiovascular or neurological issues.
- Must be able to comply with all study requirements as outlined in the consent form.
- Must be able to follow the directions of the study doctor and research team.
You likely can't join if
- Prior use of PAP machines.
- people actively using bi-level PAP or require oxygen therapy.
- people who are medically complicated or who are medically unstable ( i.e., cancer, dementia, unstable cardiac or respiratory disease, or unstable...
- Potential sleep apnea complications that, in the opinion of the clinician, may affect the health and safety of the participant.
- Inability or unwillingness to given written informed consent.
- Neuromuscular disease, hypoglossal-nerve palsy, severe restrictive or obstructive pulmonary disease, moderate-to-severe pulmonary arterial...
See the full eligibility criteria
- Must have a new diagnosis of moderate or severe OSA (i.e., AHI \> 15 events/hour).
- Must be 18-70 years old.
- No history of self-reported, uncontrolled, severe cardiovascular or neurological issues.
- Must be able to comply with all study requirements as outlined in the consent form.
- Must be able to follow the directions of the study doctor and research team.
- Must be able to understand English and be willing to provide informed consent.
- Prior use of PAP machines.
- people actively using bi-level PAP or require oxygen therapy.
- people who are medically complicated or who are medically unstable ( i.e., cancer, dementia, unstable cardiac or respiratory disease, or unstable psychiatric illness).
- Potential sleep apnea complications that, in the opinion of the clinician, may affect the health and safety of the participant.
- Inability or unwillingness to given written informed consent.
- Neuromuscular disease, hypoglossal-nerve palsy, severe restrictive or obstructive pulmonary disease, moderate-to-severe pulmonary arterial hypertension, severe valvular heart disease, New York Heart Association class...
- Pregnancy, planning to attempt to become pregnant, or breastfeeding.
The study team makes the final eligibility decision.
Where it's taking place
- Halifax, Nova Scotia, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Halifax, Nova Scotia, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.